DE3232873A1 - Pharmazeutisches praeparat - Google Patents

Pharmazeutisches praeparat

Info

Publication number
DE3232873A1
DE3232873A1 DE19823232873 DE3232873A DE3232873A1 DE 3232873 A1 DE3232873 A1 DE 3232873A1 DE 19823232873 DE19823232873 DE 19823232873 DE 3232873 A DE3232873 A DE 3232873A DE 3232873 A1 DE3232873 A1 DE 3232873A1
Authority
DE
Germany
Prior art keywords
dopa
weight
hydrocolloid
mixture
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19823232873
Other languages
German (de)
English (en)
Inventor
Prabhakar Ranchhordas 10965 Pearl River N.Y. Sheth
Jacques Levon 07058 Pine Brook N.J. Tossounian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE3232873A1 publication Critical patent/DE3232873A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19823232873 1981-09-14 1982-09-03 Pharmazeutisches praeparat Ceased DE3232873A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30149881A 1981-09-14 1981-09-14

Publications (1)

Publication Number Publication Date
DE3232873A1 true DE3232873A1 (de) 1983-03-31

Family

ID=23163649

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823232873 Ceased DE3232873A1 (de) 1981-09-14 1982-09-03 Pharmazeutisches praeparat

Country Status (11)

Country Link
JP (1) JPS5857315A (enExample)
AT (1) AT385199B (enExample)
BE (1) BE894376A (enExample)
BG (1) BG60526B2 (enExample)
CH (1) CH652025A5 (enExample)
DE (1) DE3232873A1 (enExample)
FR (1) FR2512676B1 (enExample)
GB (1) GB2105590B (enExample)
IT (1) IT1158048B (enExample)
MX (1) MX9203173A (enExample)
NL (1) NL190746C (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527852A1 (de) * 1984-08-03 1986-02-20 Nippon Shinyaku Co., Ltd., Kyoto Pharmazeutische zubereitung und verfahren zu ihrer herstellung
DE3642668A1 (de) * 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DE4101873A1 (de) * 1991-01-23 1992-07-30 Isis Chemie Gmbh Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustaende
WO1994012153A1 (en) * 1992-11-30 1994-06-09 Nystroem Christer A pharmaceutical formulation
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
US8642639B2 (en) 2004-08-12 2014-02-04 Kamprad KG Formulation for L-tryptophane comprising carbidopa/benserazide
DE102022103658A1 (de) 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
EP0198769A3 (en) * 1985-04-12 1987-09-02 Forest Laboratories, Inc. Floating sustained release therapeutic compositions
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
EP0725625B1 (en) * 1993-10-29 2000-03-22 R.P. Scherer Corporation Gelatin capsule fill able to foam
AU8000494A (en) * 1993-10-29 1995-05-22 Reckitt & Colman Products Limited Gelatin capsule fill able to foam
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
USD627230S1 (en) 2008-05-22 2010-11-16 Colgate-Palmolive Company Container
USD673861S1 (en) * 2012-03-28 2013-01-08 S.C. Johnson & Son, Inc. Dispensing system
DE102014003744A1 (de) 2014-03-10 2015-09-10 Laboratorium für Lebensmittelwissenschaft (FPE) - Eidgenössische Technische Hochschule Zürich (ETH) Produkt zur oralen Verabreichung bei Menschen oder Tieren mit mikrostrukturierten, gekapselten Inhaltsstoffen sowie Vorrichtung zum Herstellen eines derartigen Produkts und Verfahren zum Herstellen dieses Produkts

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178476A (en) * 1961-06-16 1965-04-13 Hoffmann La Roche Di-or tri-hydroxybenzyl hydrazides
US3557292A (en) * 1968-08-16 1971-01-19 Hoffmann La Roche Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
DE2611041A1 (de) * 1975-03-17 1976-10-14 Hoffmann La Roche Retard-formulierung
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713877B (en) * 1970-07-24 1972-03-29 Hoffmann La Roche Pharmaceutical composition
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178476A (en) * 1961-06-16 1965-04-13 Hoffmann La Roche Di-or tri-hydroxybenzyl hydrazides
US3557292A (en) * 1968-08-16 1971-01-19 Hoffmann La Roche Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
DE2611041A1 (de) * 1975-03-17 1976-10-14 Hoffmann La Roche Retard-formulierung
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CH-Z: Fortschritte der Arzneimittelforschung, Vol.9, 1966, S.265-271 mit Literaturvereichnis S. 295, Basel u. Stuttgart *
DE-Buch: Rote Liste 1982, Nr.69008 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527852A1 (de) * 1984-08-03 1986-02-20 Nippon Shinyaku Co., Ltd., Kyoto Pharmazeutische zubereitung und verfahren zu ihrer herstellung
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DE3642668A1 (de) * 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
DE4101873A1 (de) * 1991-01-23 1992-07-30 Isis Chemie Gmbh Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustaende
WO1994012153A1 (en) * 1992-11-30 1994-06-09 Nystroem Christer A pharmaceutical formulation
US8642639B2 (en) 2004-08-12 2014-02-04 Kamprad KG Formulation for L-tryptophane comprising carbidopa/benserazide
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
DE102022103658A1 (de) 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
WO2023156275A1 (en) 2022-02-16 2023-08-24 Joachim Kamprad Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Also Published As

Publication number Publication date
MX9203173A (es) 1992-07-01
NL8203343A (nl) 1983-04-05
BE894376A (fr) 1983-03-14
AT385199B (de) 1988-02-25
GB2105590B (en) 1985-05-30
IT8223147A0 (it) 1982-09-07
GB2105590A (en) 1983-03-30
JPS5857315A (ja) 1983-04-05
ATA341582A (de) 1987-08-15
FR2512676B1 (fr) 1987-01-23
IT8223147A1 (it) 1984-03-07
IT1158048B (it) 1987-02-18
NL190746C (nl) 1994-08-01
FR2512676A1 (fr) 1983-03-18
JPH0341447B2 (enExample) 1991-06-24
NL190746B (nl) 1994-03-01
CH652025A5 (de) 1985-10-31
BG60526B2 (bg) 1995-07-28

Similar Documents

Publication Publication Date Title
DE3232873A1 (de) Pharmazeutisches praeparat
US4424235A (en) Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
DE60133538T2 (de) Formulierung und tabletten mit guaifenesin mit verzögerter freisetzung
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
AT398165B (de) Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung
DE3779933T2 (de) Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung.
DE69623634T2 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
DE69434479T2 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
DE60319252T2 (de) Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
DE69626397T2 (de) Darifenacin enthaltende pharmazeutische zubereitungen
DE69820287T2 (de) Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst
EP0068191B2 (de) Orale Dipyridamolformen
DE3875705T2 (de) Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe.
DE69431247T2 (de) Oxybutyninformulierungen mit gesteuerter freisetzung
DE69205971T2 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
DE69110592T2 (de) Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode.
AT398166B (de) Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen)
DE69913197T2 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
DE60026459T2 (de) Simethicon enthaltendes Abführmittel
EP0804172B1 (en) Controlled release potassium dosage form
EP0108898A1 (de) Neue orale Mopidamolformen
EP0486863A1 (de) Antazida-Zubereitung mit verlängerter Magenverweilzeit
EP1509207B1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
DE69111574T2 (de) Polycarbophil-Kalzium enthaltendes Arzneimittel.
DE69526434T2 (de) Metronidazolpräparate mit modifizierter freisetzung und verfahren für ihre herstellung und verwendung

Legal Events

Date Code Title Description
8101 Request for examination as to novelty
8105 Search report available
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

8127 New person/name/address of the applicant

Owner name: F. HOFFMANN-LA ROCHE AG, BASEL, CH

8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., 8000 MUENCHEN RIEDER

8131 Rejection